Spire Healthcare shares surge 43% on Toscafund takeover proposal

Spire Healthcare shares jumped 43.3% to 215.5 pence after second-largest shareholder Toscafund proposed a non-binding cash offer of 250 pence per share, valuing the company at about £1 billion ($1.35 billion). The board said it would be minded to unanimously recommend a firm offer on those terms. Toscafund has until June 11 to either make a firm intention to proceed or withdraw.

Analysis

This is less a fundamental re-rating than a near-term probability event around takeover completion. The market is now pricing the gap between the current price and a credible cash offer, but the key second-order effect is that a controlling or near-controlling shareholder can effectively compress the timeline and reduce financing/finisher risk, which usually turns a special situation into a quasi-binary outcome within weeks rather than months. That makes the spread more about deal certainty than operating performance.

The most interesting dynamic is the signaling effect to other UK healthcare and services assets with depressed multiples and concentrated shareholder registers. If this progresses, it could encourage additional strategic or sponsor-led approaches in subscale listed healthcare platforms where public-market liquidity has been poor and cost of capital remains punitive. Competitors may not be hurt directly, but they can see valuation support spill over as investors reprice takeover optionality across the group.

The main risk is not business deterioration; it is process failure or price retrenchment if financing, diligence, or board support weakens before the deadline. With a hard date on the calendar, the stock should behave like a short-dated event trade: upside is relatively capped near the proposal level, while downside can be sharp if the bid is withdrawn, especially after a 40%+ reprice. That asymmetry makes position sizing and structure more important than directional conviction.

Consensus may be underestimating how much leverage the shareholder structure gives the bidder, but overestimating the certainty of closing at the proposed headline price. A non-binding approach from a large holder is not the same as a signed acquisition agreement, and in these situations the final 10-15p of premium often carries more execution risk than the first 20-30p. The better question is not whether the offer is attractive, but whether the market is paying too much for an outcome that is still conditional.

Key Decisions for Investors

• Long SPI only as a special-situation trade into the June 11 deadline; target the spread to 250p, but assume limited incremental upside beyond the bid level.
• For new risk, use call spreads rather than cash equity to capture deal-completion convexity while defining downside if the proposal lapses.
• If already long, trim into strength above 230p and keep a core position only if you have higher conviction that a firm offer will be announced before the deadline.
• Avoid chasing the move with an unhedged full-size long; the post-deadline downside if the offer is withdrawn can be 20%+ from elevated levels.
• If looking for relative value, pair long SPI against a basket of UK small-cap healthcare names with no takeover catalyst to isolate event optionality from sector beta.